This site has already covered the trials showing these drugs substantially reduce breathing interruptions in people with sleep apnea, and what a year of that costs. Here is the other half of the question, and it comes back empty.
What was asked
Using UK primary care records from 2007 to 2023, researchers identified adults with type 2 diabetes and a BMI of 30 or above who started either a GLP-1 or a DPP-4 inhibitor, and excluded anybody with a prior diagnosis of sleep apnea. [1] 47,315 started a GLP-1 and 159,066 a DPP-4 inhibitor, weighted to balance baseline characteristics within BMI strata, and followed for up to three years.
The comparator choice is the clever part. DPP-4 inhibitors treat diabetes and are weight-neutral. So this compares a drug that removes weight against a drug that does not, in people matched for how heavy they were — which isolates the thing everybody assumes is doing the work.
What came back
612 incident diagnoses among the GLP-1 group and 1,197 among the comparator, giving incidence rates of 5.8 and 5.4 per 1000 person-years. The hazard ratio was 1.07, with a 95% CI of 0.93 to 1.23.
That interval includes no effect and sits close to it, so this is a null rather than a harm — it is consistent with a small reduction and with a small increase, and neither is established. The finding held across BMI strata, across sexes, across individual drugs, and across multiple sensitivity analyses.
Why both results can be true
Reducing the severity of an existing condition and preventing its onset are different biological questions and different clinical ones. A drug can improve the airway of somebody whose airway is already collapsing without changing whether other people’s airways start to collapse over three years.
There is also a timing point. Sleep apnea develops over years, and three years of follow-up in a population that may not have kept taking the drug is a short window for a preventive effect to appear. The analysis was as-treated, so it measures time on the drug rather than time since starting it — but persistence in routine care is poor, and it is poor even without a bill.
What it changes about buying
If you have sleep apnea, the treatment evidence is real and it is randomized. If you are buying partly in the hope of not developing it, this is the study that speaks to that hope, and it does not support it.
That distinction is worth money. Prevention claims are open-ended — they justify paying indefinitely for something that might not have happened anyway — while treatment claims can be checked against a symptom you actually have. The honest unit for any preventive purchase is how many people must be treated for one event to be avoided, and here that number is not calculable because no reduction was found.
Nobody on this roster sells anything for sleep apnea or claims to prevent it. What they sell is weight loss, at prices in the price check, and weight loss is worth what it is worth on its own terms.